論文・技術情報追加のお知らせ

1. Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases.

酸抑制薬、ICI副作用に異なる影響。PPIsとH2RAsで特性差

対象DB：FAERS,JADER

2. Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database.

薬誘発性てんかん発作リスク、年齢別対策と監視強化必要

対象DB：FAERS

3. Postmarket review of photosensitivity associated with select BRAF and MEK inhibitors.

BRAF・MEK阻害剤による光感作リスク示唆、早期認識と対応が重要

対象DB：FAERS

4. Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER.

免疫チェックポイント阻害剤関連の神経障害を特定、迅速な認識と治療促進に貢献

対象DB：FAERS,JADER

5. Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports.

HPVワクチンの世代別安全性が改善、教育と監視がさらなる向上に寄与

対象DB：FAERS,VAERS

6. Visualization of FDA Adverse Drug Reaction Reports: Development and Usability Study of the VisDrugs Web Server.

VisDrugsはADR解析を簡略化し、安全性評価を支援

対象DB：FAERS

7. Real-world assessment of thromboembolic risk associated with tamoxifen.

タモキシフェン使用で新たな血栓イベント発見、監視強化要

対象DB：FAERS

8. Clinical adverse events to voclosporin: a real-world drug safety study based on FDA Adverse Event Reporting System.

ボクロスポリンの安全性評価が進展、慎重な使用が重要

対象DB：FAERS

9. Higher risk of gastrointestinal stenosis and obstruction in clozapine-treated individuals with schizophrenia: a pharmacovigilance study based on the FDA adverse event reporting system database.

クロザピン使用者はGSOのリスク増、長期監視要

対象DB：FAERS

10. Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin.

インクリシランは糖尿病発症リスクが低く、さらなる研究が期待される

対象DB：FAERS

11. Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System.

SSRIsとNSAIDs併用で消化管出血、血小板減少、腎障害リスク増

対象DB：FAERS

12. Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports.

フィナステリド服用若年男性で自殺傾向増、警戒必要

対象DB：FAERS

13. Study on disproportionality in the detection of potential signals between quetiapine and diabetic ketoacidosis.

クエチアピンとDKAの関連性、致命的リスク認識必要

対象DB：FAERS

14. Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0).

ニボルマブ・リラトリマブ、TRAEsリスク増加、副作用報告に注意

対象DB：FAERS

15. Targeting retinal angiogenesis: sex differences in adverse reactions to anti-VEGF therapies.

抗VEGF療法による網膜血管新生抑制、副作用に性差の影響

対象DB：FAERS

16. Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study.

PPI使用に伴う骨粗鬆症リスク、特に女性と高齢者で要警戒

対象DB：FAERS

17. Completeness of spontaneously reported adverse drug reactions in 4 databases.

ADR報告、情報欠如多発。完全性向上が重要

対象DB：CVAR,FAERS

18. Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study.

リトレシチニブ、広範な副作用報告、臨床利用で注意必要

対象DB：FAERS

19. Severe cutaneous adverse reactions associated with novel antiandrogens: A disproportionality analysis of three databases.

アパルタミド、SCARsリスクを示唆、臨床で要注意

対象DB：EudraVigilance,JADER

20. Evaluation of Adverse Events Associated with the Sulfamethoxazole/Trimethoprim Combination Drug.

ST薬の副作用、初月集中監視必要

対象DB：JADER

21. Exploring the Cardiovascular Safety Profile of Ibuprofen: Insights from EudraVigilance Database.

イブプロフェン、心血管系リスクは他NSAIDsより低いが追加研究必要

対象DB：EudraVigilance

22. Real-world safety comparison of liraglutide and semaglutide in weight management: Insights from European pharmacovigilance data.

リラグルチドとセマグルチド、安全性評価で異なる副作用傾向

対象DB：EudraVigilance

23. Characterizing Gene Therapy Medicinal Products Post-Marketing Safety Reports Based on WHO Pharmacovigilance Database, VigiBase.

遺伝子治療薬、副作用報告をVigiBaseで解析

対象DB：VigiBase

24. Adverse event reports of seizure for insomnia medication from 1967 to 2023.

不眠薬の内、オレキシン受容体拮抗薬は発作リスク低

対象DB：VigiBase

25. Hysterectomy for postpartum hemorrhage in Japan: Diagnostic code validation and nationwide descriptive analysis.

PPHに伴う子宮摘出術、緊急事例で死亡率増加

対象DB：DPC

26. Association Between Early Initiation of Anti-Herpesvirus Therapy and Outcomes in herpesvirus Encephalitis: A Nationwide Retrospective Propensity Score Analysis in Japan.

即時治療でHSEの生存率改善と医療負担軽減

対象DB：DPC

27. Ampicillin-sulbactam versus third-generation cephalosporins in aspiration Pneumonia: A nationwide retrospective cohort study.

アンピシリン治療で死亡率・感染率低減

対象DB：DPC

28. Medical costs for patients with rheumatoid arthritis who have comorbid diabetes mellitus.

糖尿病併存RA患者で医療費増、生物学的DMARD使用割合が要因

対象DB：JMDC

29. Characteristics of medical costs and resource use in patients with rheumatoid arthritis treated with and without glucocorticoids.

RA患者のグルココルチコイド使用で医療費増加、入院率も高

対象DB：JMDC

30. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study.

アビラテロン治療で心血管イベントリスク増、コルチコステロイド使用期間も長

対象DB：CPRD

31. Breathlessness intensity recorded in general practice is associated with shorter times to unplanned hospital admissions and longer lengths of stay: a UK cohort study.

息切れの強度が入院時期と滞在期間に影響、介入効果の検証が必要

対象DB：CPRD

32. Epidemiology and survival outcomes for liposarcoma patients in England: An observational cohort study using real world data.

希少がん脂肪肉腫の治療パターンと生存率を解析

対象DB：CPRD

33. Socioeconomic inequalities in disease prevalence by age and sex for 17 common long-term conditions in England: retrospective, observational study of electronic primary care records from Clinical Practice Research Datalink (CPRD) Aurum.

社会的格差で疾病率に差、中年期で最大

対象DB：CPRD

34. Risk of Ischaemic and Non-Ischaemic Heart Failure in People With Type 2 Diabetes: Observational Study in 1.6 Million People in England.

2型糖尿病では非虚血性心不全が多く、虚血性心不全リスクも高

対象DB：CPRD

35. Levothyroxine treatment for subclinical hypothyroidism and risk of adverse renal outcomes: a population-based cohort study.

レボチロキシン治療は潜在性甲状腺機能低下症の腎障害リスク軽減と無関係

対象DB：CPRD

36. Accounting for morbidity in capitation payments: A person-based workload formula for primary medical care in England.

疾病考慮の加重配分で公平性向上、貧困地域支援強化

対象DB：CPRD

37. Discontinuation of menopausal hormone therapy and risk of fracture: nested case-control studies using routinely collected primary care data.

骨折リスク、ホルモン療法中は低下、中止後1-10年で上昇、その後再低下

対象DB：CPRD

38. Developing service models for adult palliative and end of life care for people with a learning disability (The DAPPLE Project): protocol for a mixed-method study.

学習障害者の終末期ケア改善を目指す包括的研究

対象DB：CPRD

39. Investigation into Safety Profiles of Antiepileptic Drugs and Identification of Predictors for Serious Adverse Events: Insights from National Pharmacovigilance Data.

抗てんかん薬誘発ADE、特に高齢者で重篤化リスク増。薬剤選択と併用薬管理が鍵

対象DB：KAERS

40. Association Between Patients' Admission to the ICU and Psychological Disorders in Their Families: A Retrospective Matched-Pair Cohort Study.

ICU患者の家族、特に配偶者はPICS-F関連心理障害医療受診率が高い

対象DB：DeSC